tolvaptan (Samsca, SAM-sca), the first oral "vaptan" or vasopressin antagonist for treating hyponatremia

Please see FDA's April 2013 Drug Safety Communication regarding Samsca's duration of use and risk of liver injury

You'll hear about tolvaptan (Samsca, SAM-sca), the first oral "vaptan" or vasopressin antagonist for treating hyponatremia.

It's an alternative to using IV conivaptan (Vaprisol).

These are sometimes called "aquaretics" because they help eliminate extra water without sodium or potassium loss. They work by selectively blocking vasopressin receptors in the kidneys.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote